Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
125 Results for "
PLK1
" in MedChemExpress (MCE) Product Catalog:
Products (125)
125 Results for "PLK1" in MCE Product Catalog:
Cat. No.: HY-184863
CAS No.: 1034617-66-7
Target:
Research Areas:
PLK1-IN-17 is a potent PLK1 inhibitor with an IC50 of 2 nM. PLK1-IN-17 shows high selectivity for PLK2 and CDK2/A, moderate selectivity for PLK3, only weak activity against CK2, FLT3 and NEK6, and no activity against PDGFR, ALK and another 37 kinases. PLK1-IN-17 inhibits the proliferation of ovarian cancer cells and can be used in ovarian cancer-related research [1].
Cat. No.: HY-P705858
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PLK1; STPK13; Prev. PLK; Cell Cycle Regulated Protein Kinase; Serine/Threonine-Protein Kinase PLK1; Polo-Like Kinase (Drosophila); Polo-Like Kinase 1; Polo (Drosophia)-Like Kinase; Serine/Threonine-Protein Kinase 13; Polo Like Kinase 1; PLK-1
Species:
Human
Source:
E. coli
Cat. No.: HY-P705859
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PLK1; STPK13; Prev. PLK; Cell Cycle Regulated Protein Kinase; Serine/Threonine-Protein Kinase PLK1; Polo-Like Kinase (Drosophila); Polo-Like Kinase 1; Polo (Drosophia)-Like Kinase; Serine/Threonine-Protein Kinase 13; Polo Like Kinase 1; PLK-1
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-P73706
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PLK1; STPK13; Prev. PLK; Cell Cycle Regulated Protein Kinase; Serine/Threonine-Protein Kinase PLK1; Polo-Like Kinase (Drosophila); Polo-Like Kinase 1; Polo (Drosophia)-Like Kinase; Serine/Threonine-Protein Kinase 13; Polo Like Kinase 1; PLK-1
Species:
Mouse
Source:
Sf9 insect cells
Cat. No.: HY-181616
CAS No.: 3114732-99-6
Target:
Research Areas:
p53-Y220C/PLK1 modulator-1 (compound15) is a dual modulator targeting p53-Y220C and PLK1. p53-Y220C/PLK1 modulator-1 can be used in the cancer [1].
Cat. No.: HY-149085A
CAS No.: 2787626-06-4
(E)-XS-060 is an isomer of XS-060. XS-060 is a RXRα antagonist. XS-060 inhibits pRXRα-PLK1 interaction. XS-060 induces RXRα-dependent mitotic arrest. XS-060 exhibits good antitumor activity against breast cancer, lung adenocarcinoma, and liver cancer [1].
Cat. No.: HY-188141
CAS No.: 3057557-03-3
Target:
Research Areas:
Allopole-A is a Plk1 inhibitor with an IC50 of 1.4-2.5 μM against human Plk1 PBD1. Allopole-A binds to the allosteric W-F pocket in Plk1 PBD1, displacing the L2 loop, thereby disrupting water-mediated phospho-ligand binding interactions and promoting inhibitory interactions between the kinase domain and PBD to suppress Plk1 kinase activity. Allopole-A can be used in studies of human cancers with plk1 overexpression [1].
Cat. No.: HY-180991
Research Areas:
Cat. No.: HY-181001
CAS No.: 1403265-80-4
Research Areas:
POI ligand-4 is a PLK1 ligand and can be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-3 (HY-181000) [1].
Cat. No.: HY-180990
Research Areas:
Cat. No.: HY-183427
CAS No.: 2660138-04-3
Target:
Research Areas:
KBJK557 is a Plk1 PBD inhibitor with a human-derived IC50 value of 3.05 μM. KBJK577 binds to Plk1 PBD through electrostatic interactions, π-π stacking, hydrogen bonds, salt bridges and hydrophobic interactions, thereby disrupting the subcellular localization and function of Plk1. KBJK557 induces mitotic arrest, S-phase delay, G2/M-phase arrest and apoptosis, and inhibits cancer cell proliferation. KBJK557 can be used in research related to cancer and non-small cell lung cancer [1] .
Cat. No.: HY-50698A
CAS No.: 1241725-90-5
Research Areas:
(S)-BI 2536 is the enantiomer of BI 2536 (HY-50698). (S)-BI 2536 acts as an inhibitor of the BRD4 bromodomain and PLK1 kinase, with a Ki value of 54 nM against BRD4 and a Ki value of 0.42 nM against PLK1 kinase. (S)-BI 2536 exhibits anticancer activity against acute myeloid leukemia. (S)-BI 2536 can be used for the research of acute myeloid leukemia [1].
Cat. No.: HY-187593
CAS No.: 1186496-84-3
Target:
Research Areas:
PLHSpT is an inhibitor of the Polo-box domain (PBD) of Polo-like kinase 1 (Plk1), with an IC50 of 36 μM. It binds to the PB1-PB2 cleft of the Plk1 PBD to block its interaction with phosphoprotein substrates, thereby inducing mitotic arrest and apoptosis in tumor cells. PLHSpT exerts antiglioma effects when delivered via liposomes, and it is applicable to research on glioblastoma multiforme and other human cancers [1] .
Cat. No.: HY-111090
CAS No.: 929095-23-8
Target:
Research Areas:
GSK461364 analogue 1 is a thiophene-based PLK1 inhibitor with a PLK1 IC50 of 2 nM and a PLK3 IC50 of 630 nM. GSK461364 analogue 1 also acts as an inhibitor of Nek2 kinase (IC50: 21 nM). GSK461364 analogue 1 has a solubility of ≥190 μM in pH 7.4 PBS and a human plasma protein binding rate of 91.5%. GSK461364 analogue 1 can be used in studies related to colon cancer, lung cancer, breast cancer and ovarian cancer [1].
Cat. No.: HY-15828R
CAS No.: 1034616-18-6
Research Areas:
Onvansertib (Standard) is the analytical standard of Onvansertib (HY-15828). This product is intended for research and analytical applications. NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
